Martin H, McConnell I, Gorick B, Hughes-Jones N C
Clin Exp Immunol. 1987 Mar;67(3):531-6.
A purified preparation of Epstein-Barr virus (EBV) has been shown to activate the classical complement pathway by direct interaction with the first component of complement, C1, without the intervention of antibody. No evidence was found for activation of the alternative pathway. Following classical pathway activation the specific affinity of EBV for B cells can be presumed to be lost since the virus will become opsonized for clearance by phagocytic cells bearing complement receptors, CR1 and CR3. This activation is further evidence that complement plays a role in defence mechanisms independently of antibody activity.
已证明纯化的爱泼斯坦-巴尔病毒（EBV）制剂可通过与补体的第一成分C1直接相互作用来激活经典补体途径，而无需抗体的干预。未发现替代途径被激活的证据。经典途径激活后，EBV对B细胞的特异性亲和力可能会丧失，因为该病毒会被带有补体受体CR1和CR3的吞噬细胞调理以进行清除。这种激活进一步证明补体在防御机制中发挥作用，独立于抗体活性。
